KIT and sarcoma: A few kinases have been identified as drivers of cell growth in sarcoma cells (Bai et al, 2012) and four KIs have been approved for the treatment of sarcomas (Imatinib, Pazopanib, Sunitinib and Avapritinib) mostly because on the basis of inhibiting the tyrosine kinases KIT and PDGFR.